Coherus warns of temporary UDENYCA supply interruption due to packaging CMO constraints

Coherus Oncology, Inc.

Third-party CMO over-commitments cause labeling/packaging delay; API and drug product unaffected.
Channel supply projected depleted by mid-Oct; manufacturing to resume mid-Oct, product availability early Nov.
Company secures second packaging CMO; commercial supply expected Q1 2025, more than doubling capacity.
Since 2021, invested >$30M across supply chain; expects UDENYCA production cost to drop ~1/3 from current levels.
Reaffirms combined 2024 R&D and SG&A expense guidance of $250-265M, including ~$40M stock-based compensation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.